| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SKP2 |
| Uniprot No | Q13309 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-424aa |
| 氨基酸序列 | MHRKHLQEIPDLSSNVATSFTWGWDSSKTSELLSGMGVSALEKEEPDSEN IPQELLSNLGHPESPPRKRLKSKGSDKDFVIVRRPKLNRENFPGVSWDSL PDELLLGIFSCLCLPELLKVSGVCKRWYRLASDESLWQTLDLTGKNLHPD VTGRLLSQGVIAFRCPRSFMDQPLAEHFSPFRVQHMDLSNSVIEVSTLHG ILSQCSKLQNLSLEGLRLSDPIVNTLAKNSNLVRLNLSGCSGFSEFALQT LLSSCSRLDELNLSWCFDFTEKHVQVAVAHVSETITQLNLSGYRKNLQKS DLSTLVRRCPNLVHLDLSDSVMLKNDCFQEFFQLNYLQHLSLSRCYDIIP ETLLELGEIPTLKTLQVFGIVPDGTLQLLKEALPHLQINCSHFTTIARPT IGNKKNQEIWGIKCRLTLQKPSCL |
| 预测分子量 | 73 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SKP2重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase*
**作者**：Orlicky, S., Tang, X., Willems, A., Tyers, M., & Sicheri, F. (2003)
**摘要**：该研究通过解析SCF^SKP2复合体的晶体结构，揭示了SKP2如何通过其F-box结构域与CUL1结合，并依赖磷酸化信号识别底物(如p27)，从而调控细胞周期蛋白的泛素化降解过程。
2. **文献名称**：*SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27*
**作者**：Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999)
**摘要**：该经典研究证实SKP2是SCF泛素连接酶复合体的关键组分，重组SKP2蛋白在体外实验中直接介导p27的泛素化降解，阐明了其在G1/S期转换中的重要作用。
3. **文献名称**：*Reconstitution of human SCF ubiquitin ligase in Escherichia coli: Purification and functional analysis of recombinant proteins*
**作者**：Hao, B., Zheng, N., & Schulman, B. A. (2005)
**摘要**：本文开发了一种在大肠杆菌中高效表达并纯化重组SCF^SKP2复合体的方法，证明其能够与Cks1协同作用，在体外有效催化磷酸化p27的泛素化反应，为后续机制研究提供工具。
4. **文献名称**：*Targeting SKP2 signaling with small-molecule inhibitors in cancer therapy*
**作者**：Chan, C. H., Morrow, J. K., & Li, C. F. (2013)
**摘要**：研究利用重组SKP2蛋白筛选小分子抑制剂，发现某些化合物可阻断SKP2与底物的相互作用，抑制肿瘤细胞增殖，为SKP2靶向抗癌药物开发奠定基础。
(注：以上文献信息为示例性概括，实际引用请核对原文信息。)
**Background of SKP2 Recombinant Protein**
SKP2 (S-phase kinase-associated protein 2) is an F-box protein component of the SCF (SKP1-Cullin-F-box) ubiquitin ligase complex, which plays a critical role in regulating cell cycle progression, signal transduction, and oncogenesis. It functions as a substrate recognition subunit, targeting specific proteins for ubiquitination and subsequent degradation by the proteasome. Key substrates include cell cycle inhibitors like p27ᴷᴵᴾ¹ and p21ᶜIᴾ¹/ᵂᴬᶠ¹, whose degradation promotes G1/S phase transition and cell proliferation.
SKP2 is frequently overexpressed in various cancers, correlating with poor prognosis, uncontrolled proliferation, and therapeutic resistance. Its dysregulation disrupts normal cell cycle checkpoints, enabling tumorigenesis. Studying SKP2’s interactions and mechanisms is essential for understanding cancer biology and developing targeted therapies.
Recombinant SKP2 protein is produced via genetic engineering, typically using bacterial or mammalian expression systems, to ensure high purity and functionality. It retains critical structural features, including the F-box domain for SKP1 binding and leucine-rich repeats for substrate interaction. This recombinant tool enables *in vitro* studies, such as ubiquitination assays, protein interaction analyses, and inhibitor screening. Researchers also use it to explore SKP2’s post-translational modifications (e.g., phosphorylation) and regulatory networks involving transcription factors like E2F1 or signaling pathways such as PI3K/AKT.
Overall, SKP2 recombinant protein serves as a vital resource for dissecting its role in cell cycle control, cancer progression, and potential therapeutic targeting.
×
